NAWL NatureWell, Inc. Ships Products to Walgreens
LA JOLLA, Calif., Aug 28, 2001 (BUSINESS WIRE) -- NatureWell, Inc. (OTCBB:
NAWL) announced today that it has begun shipping its MigraSpray(TM) product to
the Walgreen Company.
In preparation of its anticipated national marketing campaign, the Company has
begun shipping its MigraSpray product to Walgreens regional distribution centers
across the United States. Product is expected to reach store shelves sometime in
mid-September. The Walgreen Co., Deerfield, IL, (NYSE: WAG) is the largest
national retail pharmacy chain in the United States operating 3,475 drug stores
in 43 states and Puerto Rico.
Tim Connor, CEO for NatureWell stated: "We are very excited that our MigraSpray
product will be on the shelves of a major drug store retailer as prominent as
Walgreens. This is clearly an important first step towards an intended national
launch of our products."
Commenting on the Walgreens shipment, Russ Mitchell, President of Mitchell
Health Technologies, exclusive master broker for the Company's MigraSpray and
MigraDaily(TM) products, stated today: "Obviously Walgreens is a major player in
a segment that we would like to penetrate and I am very pleased that they are
accepting shipment of our MigraSpray product. I sense a great deal of excitement
in the industry concerning the efficacy of the Company's migraine relief
products and we are optimistic that we can roll them out efficiently on a
large-scale basis."
MigraSpray is a sublingual spray containing the herb feverfew intended to
provide fast relief from migraine and many other types of headaches. MigraDaily
is a specially formulated supplement, which supports normal cerebrovasular tone.
NatureWell is an emerging company engaged in the development, marketing and
licensing of unique, proprietary healthcare products.
Statements made in this news release should be considered forward-looking and
subject to various risks and uncertainties. Such forward-looking statements are
based on management's beliefs and assumptions regarding information currently
available, and are made pursuant to the "safe harbor" provisions of the federal
securities laws. The Company's actual performance and results could differ
materially from those expressed in the forward-looking statements due to certain
risks and uncertainties that could materially impact the Company in an adverse
fashion and are only predictions of future results, and there can be no
assurance that the Company's actual results will not materially differ from
those anticipated in these forward-looking statements. Such risks and
uncertainties, include, but are not limited to, the Company's ability to secure
adequate financing, the Company's ability to ship its products in a timely
fashion, volume and timing of orders received, interruption of the manufacturing
or distribution of the Company's products or of the supplies or ingredients used
to manufacture the Company's products, the effectiveness of the Company's
products and consumer perception as to the effectiveness of the products,
competitive pricing pressures and the Company's ability to anticipate changes in
the market. The Company has no obligation to publicly update or revise any of
the forward-looking statements that may be in this news release.
CONTACT: NatureWell, Inc.
John Cole, Corporate Communications/Investor Relations
858/454-6790, Fax: 858/454-7851
URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2001 Business Wire. All rights reserved.
-0-
KEYWORD: CALIFORNIA ILLINOIS
INDUSTRY KEYWORD: ALTERNATIVE
MEDICINE
BIOTECHNOLOGY
MEDICAL
PHARMACEUTICAL
SOURCE:
NatureWell,
Inc.
*** end of story *** |
